DAPI	4′,6-diamidino-2-phenylindole
AOPs	adverse outcome pathways
AO	adverse outcome
AR	androgen receptors
BrdU	bromodeoxyuridine
CNS	central nervous system
DNT	developmental neurotoxicity
DCX	doublecortin
EDCs	endocrine-disrupting chemicals
ER	estrogen receptors
GFAP	glial fibrillary acidic protein
HI	hazard index
HQ	hazard quotients
HCIA	high content image acquisition
hiPSCs	human induced pluripotent stem cells
KE	key event
LDH	lactate dehydrogenase
LXRs	liver X/oxysterols receptors
MPO	medial preoptic area medial preoptic area
MEA	microelectrode arrays
MAP2	microtubule-associated protein 2
MIE	molecular initiating event
MBP	myelin basic protein
NPCs	neural progenitor cells
OECD	Organisation for Economic Co-operation and Development
PPARs	peroxisome proliferator-activated receptors
PBTK	physiologically based toxicokinetic
POD	point of departure
PCBs	polychlorinated biphenyls
PBDEs	polybrominated diphenyl ethers
PSD95	postsynaptic density protein 95
PR	progesterone receptor
PGE2	prostaglandin E2
QSAR	quantitative structure–activity relationship
RAR	retinoic acid receptors
RXR	retinoic X receptors
SMRI	similar mixture risk indicator
SOPs	standard operating procedures
SVZ	subventricular zone
TGs	test guidelines
TH	thyroid hormone
TR	thyroid receptors
VDR	vitamin D3 receptor